{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026337","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.920141+00:00","generated_at":"2026-06-21T06:14:11.733952+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Chief Business & Legal Officer Joseph Vittiglio resigns; COO Marc Blaustein gets retention bonus and expanded role","bullets":["Joseph Vittiglio resigns as Chief Business and Legal Officer & Secretary, effective Dec 31, 2022.","COO Marc Blaustein assumes business development and investor relations responsibilities after Vittiglio's departure.","Blaustein receives a service-based cash bonus of $83,000, payable in two equal installments (Dec 2022, June 2023).","Blaustein eligible for performance-based cash bonuses up to $332,000 tied to critical corporate objectives set by Compensation Committee.","Service-based bonus repayment required if Blaustein leaves voluntarily (non-Good Reason) or is terminated for Cause before May 31, 2023 (first installment) or Dec 31, 2023 (second)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026337","json":"https://secwatch.observer/filing/0000950170-22-026337.json","markdown":"https://secwatch.observer/filing/0000950170-22-026337.md","text":"https://secwatch.observer/filing/0000950170-22-026337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/0000950170-22-026337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/fnch-20221212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:14:11.733952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ba7f2f391","claim":"Marc Blaustein changed role as Chief Operating Officer at Finch Therapeutics Group, Inc..","evidence_excerpt":"Additionally, on December 7, 2022, the Company entered into a Retention Bonus Agreement with Marc Blaustein, the Company’s Chief Operating Officer, who will also take over business development and investor relations responsibilities following Mr. Vittiglio’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/0000950170-22-026337-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"assumed additional responsibilities"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"cf8e075739","claim":"Joseph Vittiglio resigned as Chief Business and Legal Officer and Secretary at Finch Therapeutics Group, Inc..","evidence_excerpt":"On December 7, 2022, Joseph Vittiglio informed Finch Therapeutics Group, Inc. (the “Company”) of his resignation as the Company’s Chief Business and Legal Officer and Secretary, effective as of December 31, 2022, in order to pursue other professional opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/0000950170-22-026337-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Business and Legal Officer and Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}